Grant materials appendices are read by reviewers, finance officers, ethics committees and laboratory managers. A protocol may list several peptide sequences because an in-vitro study compares pathways, runs parallel assays or uses separate controls. The phrase “no blended peptides” is a supply and documentation statement: each sequence is supplied as a separate research-use-only product, not as a pre-mixed vial. The appendix should make that distinction explicit so no-one assumes a custom cocktail exists. All materials discussed are for controlled laboratory and analytical research only; they are not for human or veterinary use.
What “No Blended Peptides” Means in a Grant Materials Appendix
In a grant appendix, “no blended peptides” should be read as a statement about product composition and traceability, not a comment on the experimental design. If the protocol lists more than one sequence, the appendix needs to show whether those sequences are separate line items, separate vials, separate batches and separate certificates of analysis. The supplier’s FAQ, as published, says it does not supply blended peptides such as Ipamorelin + CJC-1295; it recommends buying peptides individually and combining only within a controlled experimental design. That wording matters because reviewers and materials managers will look for a one-to-one relationship between the sequence named in the protocol and the item being purchased.
A blended product would normally imply a single vial containing more than one sequence, with one label and one batch record covering the mixture. A no-blend approach means the opposite: each sequence has its own catalogue entry, vial label reference, storage position and CoA link. Where the grant appendix uses shorthand such as “peptide A plus peptide B”, it should immediately clarify that this refers to two separate research materials used in the same in-vitro workflow, not a combined supplier product. This prevents procurement from requesting a custom blend that the shop does not offer and prevents reviewers from assuming a formulation that was never supplied.
The practical consequence is that the appendix should not use a single budget line to cover multiple sequences unless the line clearly states “separate vials” and lists each item. It should also avoid describing a combined working solution as though it were the purchased material. In an in-vitro laboratory workflow, a researcher may prepare an assay solution containing more than one sequence, but that is an experimental step, not a catalogue specification. The distinction belongs in the appendix because grant review often asks whether the requested materials are available, identifiable and justified. The answer is stronger when each sequence is presented as an individual research-use-only item, with batch documentation held against the relevant vial. All such materials remain not for human or veterinary use.
Documenting Multiple Sequences Without Implying a Blend
Grant appendices often compress information into tables, and compression is where ambiguity enters. A protocol may legitimately list several sequences because the study compares receptor signalling, runs concentration–response curves in cultured cells or uses negative controls. The appendix should therefore separate the scientific rationale from the supply format. A column headed “sequence or sequence panel” can list the sequences, while a separate column should state “supplied individually” or “separate vials required”. If the protocol uses a panel name, the appendix should define it plainly: for example, “panel comprises Ipamorelin 5mg and CJC-1295 (No DAC) 5mg as separate research-use-only items”, with the actual catalogue items checked against the live listing at the time of submission.
Documentation should follow the same logic. Research Sciences describes CoAs for supported products and batch-level analytical verification supporting purity, identity and contaminant screening. The appendix need not reproduce a certificate, but it should say that the batch CoA will be retained and checked. Where the shop’s current published wording refers to purity, such as ≥99%, the appendix should attribute that to the supplier’s published claim and note that the exact figure and identity details must be reconfirmed on the batch CoA. This is especially important when more than one sequence is listed, because a reviewer may otherwise assume that one certificate covers the whole panel. It does not: the relevant document is the one tied to the specific vial or batch reference supplied.
Storage statements also need to be sequence-specific and format-specific. The shop’s guidance for lyophilised peptides describes storage at –20°C or below, sealed with desiccant and protected from moisture, heat and light, with reconstituted material handled within an in-vitro laboratory workflow and stored at 2–8°C for short-term laboratory use. If the appendix says “store the peptides together”, it should mean storage in the same controlled freezer or category, not in the same vial. Individual vials reduce the risk of conflating batch references, CoAs and freeze–thaw histories. Materials managers should be able to see that each sequence is a separate item with a separate label reference, such as the SKU-and-expiry format used by the shop, and should quote that reference when raising documentation queries. The materials are research-use-only and are not for human or veterinary use.
Practical Appendix Language, Batch Traceability and Supplier Checks
Good appendix language is plain, auditable and difficult to misread. Instead of “peptide blend”, write “two individual research peptides, supplied separately, combined only in the in-vitro assay”. Instead of “mixture batch”, write “separate batches and separate CoAs; batch references to be recorded on receipt”. Instead of “one vial for the panel”, write “one vial per sequence; quantities listed by catalogue item”. This is not pedantry. It protects the grant from procurement queries, helps the laboratory avoid accidental pooling of materials and gives the materials manager a clear audit trail from protocol to purchase order to stored vial.
Where the appendix names a supplier, it should use the current trading name and check the live listing rather than an older brand reference. Research Sciences is the shop name; its FAQs describe Imperial Peptides UK as a brand within the parent company, so older documents may need a note if a legacy name appears. Catalogue items should be copied accurately from the live site at the time of writing because listings, stock and published figures can change. For a multi-sequence protocol, the appendix can include a short verification column: catalogue item, quantity, published purity claim, CoA reference or batch reference, storage condition and intended in-vitro use. If a published figure is cited, the appendix should say it reflects the supplier’s current published wording and must be reconfirmed on the live page and the batch CoA.
Supplier checks should also cover fulfilment and handling expectations without turning the appendix into a delivery promise. The shop describes tracked UK dispatch, temperature-aware storage and next-working-day dispatch in its published terms; those should be reconfirmed at the time of ordering and are not a guarantee of a specific arrival date. For grant purposes, the safer statement is that materials will be ordered as separate research-use-only items, stored under the laboratory’s controlled conditions and documented against batch CoAs. Where a grant appendix needs to show due diligence, a researcher can note that Uk peptides listings and CoAs should be checked against the exact sequence, quantity and batch reference before purchase. That check is more useful than a generic phrase such as “peptides supplied”, because it shows that multiple sequences have been handled as separate materials. The appendix should repeat, where relevant, that all products are for controlled laboratory and analytical research only and are not for human or veterinary use.
Reykjavík marine-meteorologist currently stationed in Samoa. Freya covers cyclonic weather patterns, Polynesian tattoo culture, and low-code app tutorials. She plays ukulele under banyan trees and documents coral fluorescence with a waterproof drone.